点击上方蓝字·关注我们Uni-Bio联康生物 x Qatar Economic Forum 2025很荣幸地与大家分享,联康集团董事长梁国龙先生,及董事会成员张清女士,一同受邀参加了5月20-22日在卡塔尔卢塞尔举行的第五届卡塔尔经济论坛。此次独家活动仅限受邀参与,聚集了全球有远见的嘉宾们——主要是领先公司的CEO和董事长,探讨塑造世界经济的关键力量。联康集团也正在从区域性领先者向全球化生物医药企业转型。This exclusive, invitation-only event gathers global visionaries—mainly CEOs and Chairmen of leading companies—to explore the key forces shaping the world economy. Uni-Bio is also transforming from a regional leader to a global biopharmaceutical company.随着全球生物制药产业日益融合、创新药国际化趋势不断加强,与联康的发展愿景一致,梁董事长继续围绕国际融合、产品出海及多元化增长进行跨境对话。With the increasing integration of global biopharmaceuticals and the strengthening of the internationalization trend of innovative drugs, In line with Uni-Bio’s vision, Kingsley Leung continues to engage in cross-border dialogues around international integration, product export and diversified growth.梁董事长、及与张女士合影卡塔尔经济论坛等活动提供了推动下一波全球发展的决策者之间联系的宝贵机会。Events like the Qatar Economic Forum provide valuable opportunities to connect with decision-makers driving the next wave of global development.联康集团是一家专注于内分泌、皮肤科和眼科等领域的生物制药领先企业。除中国市场外,集团着眼于国际扩展,特别是中东地区。集团正在进行PTH的FDA申请,目标将于2027年获批,这些将为PTH(博固泰®)和其他产品的全球销售拓展提供更多元化的增长机会。Uni-Bio is a leading biopharmaceutical enterprise specializing in fields such as endocrinology, dermatology and dermatology. In addition to the Chinese market, Uni-Bio also focuses on international expansion, especially in the Middle East. Uni-Bio is applying to the FDA for PTH(Bogutai®), with the goal of approval in 2027, which will provide more diversified growth opportunities for the global sales expansion of PTH and other products.END关于联康联康生物科技集团有限公司主要从事药品研发、制造及销售之业务。集团研发中心备有整套系统,用于研发基因工程药品,并设有符合国家药品监督管理局要求的实验室及中试基地。集团于北京、东莞及深圳共设有三个GMP的生产基地。集团亦拥有高效的商业化平台和营销网络。集团专注为糖尿病、骨质疏松症等内分泌治疗领域、眼科及皮肤科研发崭新的治疗方法和创新药物。联康生物科技集团有限公司于2001年11月12日在香港联合交易所主板上市,股票代号:0690。扫码关注联康集团获取更多资讯